January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
3 citations
,
January 2022 in “Russian Medical Inquiry” Atopic dermatitis may trigger alopecia areata, and early treatment can help prevent severe cases.
September 2016 in “Journal of Dermatological Science” Plasmacytoid dendritic cells, which overproduce IFN-α, may play a crucial role in starting alopecia areata, an autoimmune disease causing hair loss.
10 citations
,
January 2023 in “SAGE Open Medical Case Reports” Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
12 citations
,
March 2016 in “BBA clinical” Increased Toll-like receptors in blood cells may contribute to alopecia areata and could be a target for new treatments.
23 citations
,
July 2003 in “Journal of Investigative Dermatology” Genetic testing for hairless gene mutations is crucial to correctly diagnose and treat atrichia with papular lesions.
August 2023 in “Sabuncuoglu Serefeddin Health Sciences” CT60 polymorphism might increase the risk of Alopecia Areata.
July 2020 in “Benha Journal of Applied Sciences” Young men with early hair loss and high SAA3 levels are at higher risk for heart disease.
20 citations
,
January 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is the most effective treatment for alopecia areata.
19 citations
,
December 2011 in “PubMed” Inflammation and immunity play a key role in androgenetic alopecia, with better treatment outcomes in certain immune-positive cases.
April 2024 in “Research Square (Research Square)” A 27-year-old with APS-1 showed improvement in symptoms after treatment.
January 2026 in “Clinics and Practice” Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.
November 2025 in “JEADV Clinical Practice” Leflunomide may lower alopecia areata risk, while other immunomodulators might increase it.
Patients with acute and subacute skin lupus respond faster to belimumab than those with chronic skin lupus.
7 citations
,
January 1998 in “EXPERIMENTAL ANIMALS” The skin of both rat strains showed similar lectin binding patterns.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
46 citations
,
October 2018 in “JCI insight” CD8+ T cells are involved in alopecia areata and may cause disease relapse.
1 citations
,
May 2015 in “Zeitschrift für Gastroenterologie” Autoimmune gastritis is a common cause of iron deficiency and should be included in diagnostic guidelines.
October 2023 in “International journal of rheumatic diseases” New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
2 citations
,
January 2014 in “The Korean journal of medicine” The 2012 SLICC criteria provide an updated method for classifying Systemic Lupus Erythematosus.
ILC1-like cells may contribute to hair loss in alopecia areata.
20 citations
,
December 2010 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Decreased CD200 in hair follicles may cause immune issues in some alopecia areata cases.
November 2025 in “Biomedicines” JAK1 inhibitors can help reduce itchiness in atopic dermatitis.
14 citations
,
January 2024 in “Skin Research and Technology” The study suggested certain immune cells might cause alopecia areata, but it was retracted.
October 2025 in “Journal of Clinical Medicine” Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.
12 citations
,
August 2011 in “European Journal of Endocrinology” Anti-Müllerian hormone is a specific marker for ovarian issues in women with conditions like PCOS.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
27 citations
,
September 1992 in “The Lancet” ICL is a condition with low CD4+ T cells like AIDS but not caused by HIV, and normal CD4+ T cell counts may vary between men and women.
2 citations
,
December 2023 in “Journal of clinical immunology” Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
1 citations
,
June 2018 in “International Journal of Dermatology” DNCB is highly effective for treating alopecia areata with minimal long-term side effects.